A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
about
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.Brodalumab: First Global Approval.Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
P2860
A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A semi-mechanistic model to ch ...... n single ascending dose study.
@en
A semi-mechanistic model to ch ...... n single ascending dose study.
@nl
type
label
A semi-mechanistic model to ch ...... n single ascending dose study.
@en
A semi-mechanistic model to ch ...... n single ascending dose study.
@nl
prefLabel
A semi-mechanistic model to ch ...... n single ascending dose study.
@en
A semi-mechanistic model to ch ...... n single ascending dose study.
@nl
P2093
P2860
P356
P1476
A semi-mechanistic model to ch ...... n single ascending dose study.
@en
P2093
Christopher J Endres
David A Martin
David H Salinger
Megan A Gibbs
P2860
P304
P356
10.1002/CPDD.103
P577
2014-02-18T00:00:00Z